Harinder Gill

Queen Mary Hospital — China

Medicine · Health Sciences

31h-index3.6kcitations191works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(60), Myeloproliferative Neoplasms: Diagnosis and Treatment(46), Chronic Myeloid Leukemia Treatments(33), Retinoids in leukemia and cellular processes(24), Lymphoma Diagnosis and Treatment(13)

Publications184 total

Efficacy and safety of belumosudil for refractory chronic graft-versus-host disease in routine practice
Annals of Hematology·2026Open Access
Bringing patients and family onboard: Validation of advance care planning communication assessment tool (ACP-CAT) with patient and family perspectives
Palliative Medicine·2026
Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia
Blood·2025Open Access
Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study
Blood·2025Open Access
Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry
Blood·2025Open Access
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
The Lancet Haematology·2025
Antibiotic stewardship in suspected neutropenic fever (ASTERIC trial): a multicentre, type 1 hybrid effectiveness-implementation, stepped-wedge, randomised controlled trial study protocol
BMJ Open·2025Open Access
49 Validating advance care planning – communication assessment tool (ACP-CAT) with patients‘, families’, and clinicians’ voices
Poster·2025Open Access
MPN-524: Phase 3 Study Comparing Ropeginterferon Alfa-2b With Anagrelide As Second-Line Treatment for Essential Thrombocythemia: SURPASS-ET Trial
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MPN-524 Phase 3 Study Comparing Ropeginterferon Alfa-2b With Anagrelide As Second-Line Treatment for Essential Thrombocythemia: SURPASS-ET Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Exploring Digital Transformation in Higher Education Hurdles and Possibilities
2025
Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-risk myelofibrosis.
Journal of Clinical Oncology·2025· 1 cited
Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.
Journal of Clinical Oncology·2025
Cross-cultural adaptation and validation of the Chinese version of the quality of communication questionnaire
BMC Palliative Care·2025· 2 citedOpen Access
Challenges in Shared Care Research in Hematopoietic Cell Transplant
JAMA Oncology·2025· 1 cited
Glycosylphosphatidylinositol Biosynthesis Defect Due To Novel Biallelic Pathogenic Variants in PIGW
Pediatric Neurology·2025Open Access
Features of the electrocardiogram in TMEM43 p.S358L arrhythmogenic cardiomyopathy
Heart Rhythm·2025· 1 citedOpen Access
Transient Hemolysis Following Transcatheter Mitral Valve Replacement With a Simplified BATMAN Technique
˜The œJournal of invasive cardiology/˜The œjournal of invasive cardiology·2025
Mixed-phenotype leukemia with TCF3::ZNF384 fusion presenting as an isolated mediastinal mass
Annals of Hematology·2024Open Access
A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy
Blood·2024· 2 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Yok‐Lam Kwong(26), Yu‐Yan Hwang(12), Eric Tse(11), Thomas S. Y. Chan(8), Rita Yim(8), Anskar Y.H. Leung(8), Cyrus R. Kumana(7), Ho‐Wan Ip(5), Edmond S.K.(5), Paul Lee(5), Rock Y. Y. Leung(5), Garret M. K. Leung(5), Wai‐Kay Seto(4), Florence Loong(4), A K W Lie(4), Yammy Yung(4), Thomas Sau Yan Chan(4), Chor Sang Chim(4), James Fung(3), Albert K. W. Lie(3)